Sarcolemma integrity pathway

The sarcolemma integrity pathway comprises a series of molecular interactions and structures that maintain the stability of the muscle cell plasma membrane (sarcolemma), particularly during muscle contraction and stretching[3][6]. Key proteins include dystrophin (acting as a molecular shock absorber and scaffold), the dystrophin glycoprotein complex (DGC), sarcoglycans, dystroglycan, integrins, and sarcospan, which together physically connect the cytoskeleton to the extracellular matrix[1][3]. Disruption of this pathway leads to increased vulnerability of muscle fibers to mechanical stress and is central to the pathophysiology of muscular dystrophies[3][4][6]. While the pathway itself is not a direct therapeutic target, several of its protein components are, either through drug or gene therapy—a notable example being metformin, which can induce sarcolemma stabilization via increased expression of α-dystroglycan[4].

Other names

Sarcolemma integrity mechanismsSarcolemma stabilization pathwayMuscle membrane stability pathwayDystrophin glycoprotein complex (DGC) stabilization pathway

For metformin: upregulation of α-dystroglycan, modulates metabolic and glycosylation pathways, improves membrane strength. For gene therapies or biologics: restoration of missing/stabilizing components of the dystrophin glycoprotein complex (DGC), improvement of glycosylation and ECM binding.